Valuation: Pharmena S.A.

Market Cap 35.08M 9.25M 8.09M 7.46M 6.88M 12.97M 891M 13.25M 89.2M 436M 34.75M 33.99M 1.5B P/E 2024
-33.8x
P/E 2025 -10.4x
Enterprise Value 35.09M 9.26M 8.09M 7.46M 6.88M 12.97M 891M 13.26M 89.22M 437M 34.76M 34M 1.5B EV / Sales 2024
154x
EV / Sales 2025 18.4x
Free-Float
29.7%
Yield 2024 *
-
Yield 2025 -
1 month-0.63%
3 months-10.00%
6 months-4.55%
Current year+21.15%
1 week 3.05
Extreme 3.05
3.15
1 month 3.02
Extreme 3.02
3.26
Current year 2.56
Extreme 2.56
4.32
1 year 2.5
Extreme 2.5
4.32
3 years 2.5
Extreme 2.5
9.18
5 years 2.5
Extreme 2.5
11.38
10 years 2.5
Extreme 2.5
33.48
Manager TitleAgeSince
Chief Executive Officer - 12/11/2002
Chief Tech/Sci/R&D Officer - 01/04/2008
Director TitleAgeSince
Director/Board Member 62 -
Director/Board Member 63 -
Chairman 52 25/06/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-12.26%-55.88% 9.25M
+0.10%+0.20%+5.30%-6.51% 233B
+1.53%-0.20%+35.51% - 50.18B
+1.95%+4.80%+131.18% - 9.89B
+1.19%+11.07%+27.18%-50.98% 7.53B
+2.98%+1.06%-8.26%+17.80% 5.17B
-1.07%-3.99%-37.35%-38.34% 4.34B
+0.42%+3.31%-4.84%-9.46% 3.95B
-5.80%-1.72%-30.51%-48.97% 3.28B
-1.28%+1.87%-18.28%-47.37% 2.63B
Average +0.00%+1.91%+8.77%-29.96% 32.02B
Weighted average by Cap. +0.37%+0.55%+12.95%-8.85%

Financials

2024 2025
Net sales 268K 70.69K 61.78K 57.01K 52.55K 99.04K 6.81M 101K 681K 3.33M 265K 260K 11.48M 1.58M 416K 364K 335K 309K 583K 40.06M 596K 4.01M 19.62M 1.56M 1.53M 67.54M
Net income -1.26M -333K -291K -268K -247K -466K -32.06M -477K -3.21M -15.7M -1.25M -1.22M -54.05M -2.77M -730K -638K -589K -543K -1.02M -70.34M -1.05M -7.04M -34.45M -2.74M -2.68M -119M
Net Debt -1.5M -396K -346K -319K -294K -555K -38.13M -567K -3.82M -18.67M -1.49M -1.45M -64.28M 9K 2.37K 2.07K 1.91K 1.76K 3.33K 229K 3.4K 22.88K 112K 8.92K 8.72K 385K
Logo Pharmena S.A.
Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
Employees
7
Date Price Change Volume
17/07/26 PLN 3.150 0.00% 25
16/07/26 PLN 3.150 +0.32% 35
15/07/26 PLN 3.140 -0.32% 334
14/07/26 PLN 3.150 +1.29% 1,210
13/07/26 PLN 3.110 -1.27% 743